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Abstract Cyclin B is a central regulator of transition from the
G2 phase of the cell cycle to mitosis. In mammalian cells two
B-type cyclins have been characterised, cyclin B1 and B2. Both
are expressed with a maximum in G2 and their synthesis is
mainly regulated on the transcriptional level. We show that a
single cell cycle genes homology region, lacking a functional cell
cycle-dependent element in tandem with it, contributes most of
the cell cycle-dependent transcription from the cyclin B1 pro-
moter. The coactivator p300 binds to the cyclin B1 promoter
and synergises with the transcription factor NF-Y in activating
transcription of cyclin B1.
) 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Cyclins are central regulators of the cell division cycle. They
have been found to associate with cyclin-dependent kinases
and thereby modulate their kinase activity [1]. Cyclin B forms
a complex with the cdc2 protein kinase (cyclin-dependent
kinase 1, cdk1) yielding the maturation-promoting factor
(MPF) [2,3]. The MPF complex is essential for the transition
from G2 to mitosis. It functions also in controlling this check-
point and is conserved in all eukaryotes [4^6].
In mammals two cyclin B forms have been characterised,
cyclin B1 and cyclin B2. The function of cyclin B1 cannot be
replaced by other proteins since knockout mice for the cyclin
B1 gene die in utero. However, cyclin B2-null mice are viable.
Therefore, it seems that cyclin B1 can compensate for loss of
cyclin B2, but not vice versa. Although cyclin B2 (3/3) mice
appear to be normal, they seem to be less fertile and tend to
be slightly smaller [7]. Distinct roles for the di¡erent forms of
cyclin B have been suggested by their subcellular distribution.
While cyclin B1 co-localises with microtubules, cyclin B2 as-
sociates with the Golgi apparatus [8]. However, most proper-
ties, including timing of their expression, indicate similar func-
tions for the two proteins.
Cyclin protein levels oscillate during the cell cycle. B-type
cyclins appear in S phase and accumulate in G2 and mitosis
before disappearing at transition from metaphase to ana-
phase. Synthesis of cyclin B during the cell cycle is mainly
regulated on the transcriptional level [9]. For the cyclin B2
gene we found that the transcription factor NF-Y is the
main activator employing three CCAAT-boxes in the B2 pro-
moter [10]. Cell cycle-regulated transcription from this pro-
moter is regulated by a cell cycle-dependent element (CDE)
and cell cycle genes homology region (CHR) tandem element
[11]. We had shown earlier for the transcription of cdc25C,
cyclin A and cdc2 genes that CDE/CHR elements repress tran-
scription in the early phases of the cell cycle. Relief from this
repression later in S and G2 leads to the expression of these
genes [12]. Later during mitosis, degradation by ubiquitin-
mediated proteolysis leads to the impressive drop in cyclin
B protein levels [9,13,14].
In regard to the cyclin B1 cell cycle expression, two reports
describe opposing results both implicating an E-box in tran-
scriptional regulation of this gene, binding either the upstream
stimulatory factor USF or the inhibitor Max [15,16]. In these
reports the E-box serves as an activating site in one report or
as a repressing element in the other, which is possibly con-
nected to the use of di¡erent cellular systems in the two stud-
ies. Both reports attribute only about a two-fold regulation
between resting and G2/M cells to this E-box during the cell
cycle. Furthermore, the more recent of the two papers con-
cludes that there have to be additional regulatory elements to
account for full cell cycle-dependent regulation with the main
contribution residing in other parts of the cyclin B1 promoter
[15,16]. Recently, two other studies present evidence that the
cyclin B1 promoter is also subject to activation by c-Myc:
binding of c-Myc to the activating E-box could be shown
by electrophoretic mobility shift assays and chromatin immu-
noprecipitation (ChIP) [17,18].
Here, we describe that cyclin B1 employs a CHR for cell
cycle-dependent transcription and that the coactivator and
histone acetyltransferase protein p300 enhances activation of
cyclin B1 transcription.
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2. Materials and methods
2.1. Cell culture, transfections and £uorescence-activated cell sorting
(FACS) analyses
NIH3T3 cells (DSMZ, Braunschweig, Germany) for cell cycle anal-
yses were cultured and transfected as previously described [19].
Human foreskin ¢broblasts (HFF) were cultured in a humidi¢ed
atmosphere with 10% CO2 at 37‡C with Dulbecco’s modi¢ed Eagle’s
medium (DMEM) supplemented with 10% foetal calf serum (FCS,
Biochrom, Berlin, Germany). For cell cycle analysis, cells were cul-
tured for 48 h in DMEM without FCS. After this time cells were
harvested for 0 h time points. The ¢broblasts were stimulated with
20% FCS in DMEM to re-enter the cell cycle and subsequently ana-
lysed at indicated time points. FACS analyses were performed as
described previously [19].
SaOS-2 cells (DSMZ) were cultured and transfected as described
earlier [19,20]. Transfections using the expression plasmids for wild-
type p300 (kindly provided by Antonio Giordano) [21], NF-YA, NF-
YB and NF-YC [22] were carried out using Fugene 6 (Roche, Mann-
heim, Germany), according to the manufacturer’s suggestions, with
0.8 Wg hB1-Luci, 0.016 Wg pRL-null vector per assay (Promega,
Mannheim, Germany) and increasing amounts of p300 and the three
NF-Y subunit-expressing constructs. The total amount of transfected
DNA was held constant by adding pcDNA3.1HisC (Invitrogen, Bre-
da, The Netherlands) plasmid. Luciferase assays were done as re-
ported earlier [19].
2.2. RNA extraction and reverse transcription (RT)-PCR analysis
Total RNA extraction from NIH3T3 and HFF cells was carried out
with TRIzol Reagent (Invitrogen) as suggested by the manufacturer.
Real-time RT-PCR mRNA quanti¢cation was done with the Light-
Cycler system (Roche). Speci¢c primers for human cyclin B1 5P-AA-
GAGCTTTAAACTTTGGTCTGGG-3P ; 5P-CTTTGTAAGTCCTT-
GATTTACCATG-3P (GenBank accession number M25753) and
mouse cyclin B1 5P-CAGAGTTCTGAACTTCAGCCTG-3P ; 5P-TT-
GTGAGGCCACAGTTCACCAT-3P (GenBank accession number
X64713) were used at 1 WM with 0.5 mM MgCl2 on 50 ng total
RNA template in the QuantiTect SYBR Green RT-PCR mix (Qiagen,
Hilden, Germany). The reverse transcriptase reaction was performed
at 50‡C for 20 min. Each cycle of the subsequent PCR included 15 s
denaturation at 94‡C, 20 s of primer annealing (55‡C) and 15 s of
extension/synthesis (72‡C). Product quanti¢cation was optimal at
78‡C. Calculations were carried out as described [23].
2.3. Western blot analysis
Western blots were prepared essentially as previously described [23].
A 1:200 dilution of the mouse monoclonal anti-cyclin B1 antibody
(GNS1, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was em-
ployed and analysed with Super Signal West Chemiluminescent sub-
strate (Pierce, Perbio Science, Bonn, Germany) according to the man-
ufacturer’s instructions. Signals were recorded with a Luminescent
Image Analyzer LAS-100 (Fuji, Du«sseldorf, Germany). The blot
was stripped and reprobed with a 1:5000 dilution of the mouse mono-
clonal anti-L-actin antibody (clone AC-15, Sigma, Taufkirchen, Ger-
many).
2.4. Cloning of the human cyclin B1 promoter and creation of
plasmid constructs
The cyclin B1-promoter ¢re£y luciferase reporter construct hB1-
Luci was obtained by PCR ampli¢cation with the primers B1-for 5P-
CGGGTACCGTGACTTCCAGCGCCAGGAGTCTCTATC-3P and
B1-rev 5P-CATGCCATGGCTTCCTCTTCACCAGGCAGCAGCT-
C-3P followed by cloning at KpnI/NcoI sites into the pGL3-Basic
vector (Promega, Mannheim, Germany). Sequencing of the ¢nal con-
struct yielded the published sequence [15] (GenBank accession number
U22364).
Promoter mutants were created by PCR-based targeted mutagenesis
on the basis of hB1-Luci employing the primers CDEmut-for 5P-AG-
GCCAATAAGGAGGGAGCATTACGGG-3P, CDEmut-rev 5P-TC-
AGATTTAAACCCCGTAATGCTC-3P, CHRmut-for 5P-GAGGGA-
GCAGTGCGGGGTGCATATCTG-3P, CHRmut-rev 5P-AGCCAG-
CCTAGCCTCAGATATGCACCC-3P.
2.5. ChIP assays
ChIPs were carried out guided by a published procedure [24].
NIH3T3 cells were crosslinked with 1% formaldehyde for 18 h after
serum restimulation. p300 protein crosslinks were precipitated using
1 Wg of rabbit polyclonal anti-p300 antibody (C-20, Santa Cruz Bio-
technology). As negative control served a mixture of 0.5 Wg mouse
monoclonal anti-cyclin B1 antibody (GNS1, Santa Cruz Biotechnol-
ogy) and 0.5 Wg goat polyclonal anti-cyclin B2 antibody (N-20, Santa
Cruz Biotechnology). Samples were analysed using Taq DNA Poly-
merase (Qiagen) according to the manufacturer’s suggestions with the
following primers: mouse cyclin B1 5P-GACTTGTGCGCAGGCA-
TAGAGC-3P and 5P-GACACCCTAACCTCTGGCTATC-3P (Gen-
Bank accession number AC112701); mouse K-globin 5P-GGG-
CAACTGATAAGGATT-3P and 5P-AGCACCATGGCCACCAAT-
CT-3P (GenBank accession number X05379). PCR products were
run on a 3% agarose gel and stained with SYBR Green (Biozym,
Hess. Oldendorf, Germany).
3. Results and discussion
3.1. Cell cycle-dependent expression of cyclin B1
The central characteristic of cyclins is their periodical ap-
pearance during the cell division cycle. We tested expression
of cyclin B1 during cell division in mouse NIH3T3 cells and
HFF on the mRNA and protein level (Fig. 1). Through serum
deprivation cells were led into the G0 phase which is given as
the 0 h time point. Addition of serum to the medium stimu-
lated the cells to proceed through the cell cycle. At various
time points samples were analysed for mRNA, protein and
DNA content per cell. Cyclin B1 mRNA appears when most
cells are in G2/M. Hardly any expression is seen in G0 cells
and when cells go through G1 and S phases (Fig. 1A,B).
When a substantial portion of the NIH3T3 cells enter G2 after
about 18 h of restimulation, the cyclin B1 mRNA concentra-
tion strongly increases and accumulates until the time when
cells become more asynchronous at about 24 h. In human
¢broblasts expression of cyclin B1 mRNA is similar. How-
ever, the human cells reach the point at which most cells
are in G2 about 6 h later than the mouse cells (Fig. 1C and
data not shown). Cyclin B1 protein is expressed with the same
kinetics lagging about 2 h behind the mRNA expression (Fig.
1D). Taken together, these observations show that cyclin B1 is
expressed in G2/M and that the appearance of cyclin B1 pro-
tein follows the rise of cyclin B2 mRNA indicating that the
regulation of transcription determines the timing of cyclin B1
protein synthesis. These results are similar to the ¢ndings seen
for the expression of cyclin B2 [11]. Our results are consistent
with previous observations where cyclin B1 expression was
examined in cells after thymidine or nocodazole block [7,25].
Expression timing detected here is also in agreement with a
cyclin B1 function at G2/M transition.
3.2. Nucleotide sequence conservation of regulatory sites in
cyclin B promoters
A comparison of human and mouse cyclin B1 and cyclin B2
upstream regulatory regions pinpoints conserved sites (Fig. 2).
Although the overall nucleotide identity is low, we ¢nd dis-
tinct regions of similarity. Most strikingly, the two CCAAT-
boxes, which bind to NF-Y trimeric transcription factors, are
not only perfectly identical in their nucleotide sequence in all
four promoters but also their distances are conserved. In cy-
clin B1 the distance of 32 bp and in the cyclin B2 promoter of
33 bp are constant in both human and mouse promoters (Fig.
2). The functional importance of these NF-Y binding sites as
the dominant activating elements has been documented for
the mouse cyclin B2 and human cyclin B1 promoters [10,26].
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Fig. 1. Cell cycle-dependent expression of chromosomally derived cyclin B1. NIH3T3 mouse ¢broblasts and HFF were serum-starved and re-
stimulated by addition of serum to the medium. After 48 h of starvation, the 0 h time point represents cells mostly resting in G0. The following
time points give results after serum restimulation. A: Cyclin B1 mRNA expression from NIH3T3 cells as measured by RT-PCR standardised
relative to total RNA; averages of two experiments are given. B: FACS analyses of NIH3T3 cell populations at selected time points before
and after serum addition. Cells were stained with propidium iodide and measured for DNA staining per cell. C: Expression of cyclin B1
mRNA in HFF cells with total RNA as standard quanti¢ed by RT-PCR. Averages of two experiments are given. D: Cyclin B1 protein expres-
sion detected by immunoblotting. L-Actin served as a loading control.
    
    
  
  
 
 
 
  
  
  
  
    
Fig. 2. Comparison of nucleotide sequences from cyclin B promoters. Conserved elements are indicated in bold. CDE, CHR and CCAAT-boxes
identi¢ed earlier in the cyclin B2 promoter [10,11] together with the related sites in the cyclin B1 promoters are boxed. Numbering is relative to
the translational start codons.
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It appears that activation by NF-Y through conserved
CCAAT-boxes is a general feature of cyclin B promoters.
The elements responsible for cell cycle-dependent transcrip-
tion cannot be delineated so easily. In the case of genes ex-
pressed in G2/M, like cyclin B2, a mechanism which includes
CDE/CHR elements has been depicted [11,12]. For cyclin B1
two reports had implicated an E-box in cell cycle regulation of
this gene [15,16]. We compared the upstream regions of hu-
man to mouse cyclin B1 genes and found that the E-box
region from the human promoter is not conserved in the
mouse (Fig. 2). Two essential nucleotides of the 5P-
CANNTG-3P E-box consensus are changed in the respective
mouse sequence. Given the sequence-speci¢c requirements of
HLH proteins acting on E-boxes, taken together with results
on E-box regulation of cyclin B1 summarised in the introduc-
tion, we are tempted to conclude that this element is unlikely
to be the only responsible for cell cycle-dependent transcrip-
tional regulation in the cyclin B1 promoter.
In search for other cell cycle elements the alignment in Fig. 2
yielded some similarity in the CDE/CHR tandem element
previously found to regulate cell cycle-dependent transcription
in the mouse cyclin B2 promoter [11]. This region in the cyclin
B1 promoter had been analysed once, but only found irrele-
vant for the activation by a forkhead transcription factor and
not tested for cell cycle relevance [27]. In the CDE region we
hardly ¢nd any nucleotides which are conserved in all four
genes (Fig. 2). However, the CHR is, with the exception of
one nucleotide, identical in all four promoters.
3.3. A new CHR-like site regulates cell cycle-dependent
repression of cyclin B1 transcription
In order to elucidate a potential function of these homolo-
gous sites for transcriptional regulation of cyclin B1 expres-
sion we tested wild-type and mutant reporter constructs. To
this end, we cloned the human cyclin B1 promoter from the
translational start codon up to 1133 bp of the upstream region
into the ¢re£y luciferase-expressing reporter plasmid hB1-
Luci. A similar construct had previously been shown to confer
cell cycle-dependent transcription [28] consistent with the tim-
ing seen for expression from the chromosomal gene (Fig. 1).
Therefore, such a construct can be employed to assay for cell
cycle regulation.
We compared this wild-type construct with mutants in the
putative CDE and CHR sites in transfected cells which were
serum-starved and restimulated. As a measure for cell cycle
regulation of promoter constructs, ratios of luciferase activi-
ties from G2/M to values from G0 cells were calculated (Fig.
3). In this assay the wild-type cyclin B1 construct displays a
cell cycle stimulation of more than six-fold. The mutation in
the putative CDE changes regulation only marginally, which
had been observed earlier [28]. However, alteration of the so
far untried CHR-like site left only a small remaining regula-
tion of about two-fold (Fig. 3). This loss of regulation is due
to an increase of activity in resting cells rather than a further
stimulation of transcription in cells in later cell cycle phases
(data not shown). The implied loss of repression is a general
feature of CHR-dependent regulation and has been observed
with all CHRs identi¢ed so far. This regulation seen in the
cyclin B1 promoter is resembling that seen in the cyclin B2
promoter [11,12].
Fig. 3. Expression from a cyclin B1-promoter luciferase reporter
comparing activity in G2/M versus resting cells. Mutation of the
CHR leads to a loss of cell cycle regulation. Luciferase reporter
plasmids carrying the human cyclin B1 upstream region together
with a Renilla luciferase-expressing control plasmid were transfected
into NIH3T3 ¢broblasts. Cells were synchronised by serum starva-
tion for 66 h and restimulated. Ratios of luciferase activities from
cell lysates 24 h after restimulation to activities in resting cells are
given. Averages with standard deviations from six experiments are
shown. Renilla luciferase was employed to standardise cyclin B1 ¢re-
£y luciferase reporter expression.
Fig. 4. p300 activates transcription from the cyclin B1 gene and
binds to its promoter. A: Increasing amounts of plasmids expressing
the three subunits of NF-Y (A, B and C) and p300 were cotrans-
fected with the cyclin B1 promoter reporter and a Renilla luciferase
control plasmid in SaOS-2 cells. The total amount of DNA was
held constant in all transfections by adding an irrelevant plasmid.
Fire£y luciferase was measured and standardised to Renilla lucifer-
ase activity. Expression from the cyclin B1 promoter without co-
transfection was set at 100%. Assays from three independent experi-
ments with standard deviations are shown. B: ChIP experiments
with antibody directed against p300 on the cyclin B1 promoter. The
antibodies used in the control lane were directed against non-DNA
binding protein. The K-globin gene served as negative control pro-
moter.
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Thus, a marked di¡erence between cyclin B1 and B2 regu-
lation lies in the function of the CDEs. The region upstream
of the CHR described here for the cyclin B1 promoter plays
hardly any role in cell cycle-dependent transcription. Cell
cycle regulation resides mostly in a novel CHR (Figs. 2 and
3). A variable contribution of the CDE in CDE/CHR tandem
elements has been observed since the ¢rst description of this
regulatory mechanism. In our original paper, cell cycle regu-
lation of cyclin A, cdc2 and human cdc25C promoters was
based equally on intact CDE and CHR sites [12]. In the
mouse cyclin B2 promoter contribution of the CHR was
more pronounced than that of the CDE [11]. Recently, we
discovered a CHR in the mouse cdc25C promoter which
does not require a CDE in conjunction with the CHR [19].
Taken together, we demonstrate that a novel CHR with the
sequence 5P-TTTAAA-3P, which is di¡erent from the previ-
ously established consensus of 5P-TTTGAA-3P, has a central
role in cell cycle-dependent transcription of the cyclin B1 pro-
moter.
3.4. The coactivator p300 stimulates cyclin B1 transcription
and binds to its promoter
The members of the p300/CBP protein family, which dis-
play histone acetyltransferase activity, had been shown to be
coactivators in many growth-related systems [29]. Since cyclin
B1 is important for growth control, we wondered if these
coactivators can function in transcriptional activation of the
cyclin B1 gene. We cotransfected the wild-type cyclin B1 re-
porter with increasing amounts of a plasmid expressing p300
(Fig. 4A). A modest increase in reporter activity is observed.
In parallel, assays were carried out in which the three subunits
making up the NF-Y transcription factor were tested. Increas-
ing expression of NF-Y leads to a similar increase of tran-
scription from the cyclin B1 promoter. The third part of the
experiment combines the lower plasmid amount transfections
of p300 and NF-Y in one series of cotransfections. At the
highest plasmid quantity, which is still smaller than what
could be used for p300 and NF-Y individually, stimulation
over the control without cotransfection is more than three-
fold. Considering the limitation in the total amount of
DNA, which could be cotransfected when combinations of
NF-Y- and p300-expressing plasmids were used, it appears
that NF-Y and p300 synergise in the activation of the cyclin
B1 promoter (Fig. 4A).
To test for in vivo protein binding of p300 to the promoter
we performed ChIP assays. Employing the DNA fragment
carrying the conserved CCAAT-boxes in ChIPs yielded a sig-
nal for p300 on the cyclin B1 promoter (Fig. 4B).
In summary, our experiments indicate a single CHR site to
contribute most to the cell cycle-dependent transcription of
the cyclin B1 promoter. Furthermore, the coactivator p300
binds to the promoter and synergises with NF-Y in the acti-
vation of cyclin B1 transcription.
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